Francesco Frattini, Stefano Rausei, Corrado Chiappa, Francesca Rovera, Luigi Boni, Gianlorenzo Dionigi, Department of Surgical Sciences, University of Insubria School of Medicine, 21100 Varese, Italy.
World J Gastrointest Surg. 2013 May 27;5(5):135-7. doi: 10.4240/wjgs.v5.i5.135.
Positive peritoneal cytology in gastric cancer is classified as M1 disease by the 7(th) Edition of American Joint Committee on Cancer staging system. With the introduction of laparoscopy and peritoneal washing cytology in the staging of gastric cancer a new category of patients has been identified. These are patients with no macroscopic peritoneal metastases but with peritoneal cytology positive (P0C1). Prognosis and treatment of such patients represent a controversial issue. We evaluate the state of the art of staging system in gastric cancer and discuss standardisation in staging and treatment procedures. There is still a lack of uniformity in the use of laparoscopy with peritoneal cytology in clinical decision making and in the surgical treatment for gastric cancer. Survival of this patient subset remains poor. Multimodal therapies and new therapeutic strategies are required to improve the survival of these patients.
胃癌的阳性腹膜细胞学检查被美国癌症联合委员会第 7 版分期系统归类为 M1 疾病。随着腹腔镜和腹膜冲洗细胞学检查在胃癌分期中的引入,已经确定了一类新的患者。这些患者没有肉眼可见的腹膜转移,但腹膜细胞学阳性(P0C1)。这些患者的预后和治疗是一个有争议的问题。我们评估了胃癌分期系统的最新进展,并讨论了分期和治疗程序的标准化。在临床决策和胃癌手术治疗中,腹腔镜联合腹膜细胞学的使用仍然缺乏一致性。这部分患者的生存率仍然较差。需要采用多模式治疗和新的治疗策略来提高这些患者的生存率。